Patents Assigned to Shanghai Allist Pharmaceuticals, Inc.
-
Patent number: 10072002Abstract: The present invention relates to pyridinylaminopyrimidine derivatives represented by the following formula (I), and pharmaceutically acceptable salts, preparation process and use thereof, wherein R1, R2, R3, R4, R5, m and A are defined as in the description. Pyridinylaminopyrimidine derivatives of the present invention can selectively inhibit the activity of mutant-type epidermal growth factor receptor (EGFR), have a good inhibition for the cancer cell proliferation, and therefore can be used as a therapeutic agent for treating tumors and relevant diseases.Type: GrantFiled: July 29, 2015Date of Patent: September 11, 2018Assignee: Shanghai Allist Pharmaceuticals, Inc.Inventors: Huibing Luo, Huayong Zhou, Shuhui Wang, Yong Wu
-
Patent number: 9102629Abstract: The present invention relates to polymorphic forms of N-{4-[3-chloro-4-(3-fluoro-benzyloxy)phenylamino]-quinazolin-6-yl}-acrylamide p-toluenesulfonate with the characteristic X-ray powder diffraction data as stated in the description, preparation methods thereof, pharmaceutical compositions comprising the same and the use thereof.Type: GrantFiled: November 18, 2014Date of Patent: August 11, 2015Assignee: SHANGHAI ALLIST PHARMACEUTICALS, INC.Inventors: Jianhui Guo, Yong Jiang
-
Patent number: 8952002Abstract: The present invention refers to aminoheteroaryl compounds of the following formula (I) as well as the preparation method and use thereof, wherein R1 and R3 are defined in the Description in details. The aminoheteroaryl compounds of the present invention are inhibitors of hepatocyte growth factor receptor (c-Met), have favorable inhibitory effect against c-Met and inhibitory effect against the proliferation of cancer cells, such that they may be used as therapeutic agents for the treatment of tumors and related diseases.Type: GrantFiled: January 17, 2013Date of Patent: February 10, 2015Assignee: Shanghai Allist Pharmaceuticals, Inc.Inventor: Huibing Luo
-
Patent number: 8937079Abstract: The present invention relates to polymorphic forms of N-{4-[3-chloro-4-(3-fluoro-benzyloxy)phenylamino]-quinazolin-6-yl}-acrylamide p-toluenesulfonate with the characteristic X-ray powder diffraction data as stated in the description, preparation methods thereof, pharmaceutical compositions comprising the same and the use thereof.Type: GrantFiled: November 19, 2012Date of Patent: January 20, 2015Assignee: Shanghai Allist Pharmaceuticals, Inc.Inventors: Jianhui Guo, Yong Jiang
-
Publication number: 20140357613Abstract: The present invention refers to aminoheteroaryl compounds of the following formula (I) as well as the preparation method and use thereof, wherein R1 and R3 are defined in the Description in details. The aminoheteroaryl compounds of the present invention are inhibitors of hepatocyte growth factor receptor (c-Met), have favorable inhibitory effect against c-Met and inhibitory effect against the proliferation of cancer cells, such that they may be used as therapeutic agents for the treatment of tumors and related diseases.Type: ApplicationFiled: January 17, 2013Publication date: December 4, 2014Applicant: SHANGHAI ALLIST PHARMACEUTICALS, INC.Inventor: Huibing Luo
-
Patent number: 8871726Abstract: The present invention relates to a C-aryl glucoside derivative of Formula (I) below, a preparation method therefor and a use thereof, wherein X, R1, R2, R3, R4, m and n are as defined in specification. The derivative of the present invention is a sodium-glucose co-transporter 2 (SGLT-2) inhibitor associated with glucose reabsorption of bowel or kidney, and has a good urine glucose excreting effect, thus being useful as a therapeutic agent for treating diabetes and related diseases.Type: GrantFiled: October 27, 2011Date of Patent: October 28, 2014Assignee: Shanghai Allist Pharmaceuticals, Inc.Inventor: Huibing Luo
-
Publication number: 20130225514Abstract: The present invention relates to a C-aryl glucoside derivative of Formula (I) below, a preparation method therefor and a use thereof, wherein X, R1, R2, R3, R4, m and n are as defined in specification. The derivative of the present invention is a sodium-glucose co-transporter 2 (SGLT-2) inhibitor associated with glucose reabsorption of bowel or kidney, and has a good urine glucose excreting effect, thus being useful as a therapeutic agent for treating diabetes and related diseases.Type: ApplicationFiled: October 27, 2011Publication date: August 29, 2013Applicant: SHANGHAI ALLIST PHARMACEUTICALS, INC.Inventor: Huibing Luo
-
Patent number: 8507010Abstract: The present invention provides a pharmaceutical composition, useful for the treatment of diseases characterized by abnormal PTKs activity of erbB family in a mammal, comprising pharmaceutically acceptable salts of N-{4-[3-chloro-4-(3-fluoro-benzyloxy) phenylamino]quinazolin-6-yl}-acrylamide, optionally a pharmaceutically applicable carrier or diluent, and a stabilizer having a dispersing and/or protective effect on the active ingredient. The present invention further provides a pharmaceutical formulation comprising said composition, methods for preparation of said composition and said formulation, as well as use of said composition and said formulation for treating diseases characterized by abnormal PTKs activity of erbB family in a mammal.Type: GrantFiled: May 21, 2009Date of Patent: August 13, 2013Assignee: Shanghai Allist Pharmaceuticals, Inc.Inventors: Jianhui Guo, Haiying He
-
Patent number: 8455526Abstract: The invention discloses the use of 2-butyl-4-chloro-1-[2?-(1H-tetrazol-5-yl)1,1?-biphenyl-methyl]-imidazole-5-carboxylic acid, 1-[(isopropoxycarbonyl)oxy] methyl ester and the pharmaceutically acceptable salts thereof in the manufacture of a medicament for the treatment of the damage of a target organ caused by hypertension. It particularly discloses the use of this compound in the manufacture of a medicament for the treatment of left ventricular hypertrophy, renal dysfunction, aorta thickening caused by hypertension, which provides an effective drug and method for the treatment of the damage of target organs for hypertension patients.Type: GrantFiled: June 6, 2008Date of Patent: June 4, 2013Assignee: Shanghai Allist Pharmaceuticals, Inc.Inventor: Jianhui Guo
-
Patent number: 8349854Abstract: The present invention relates to salt forms of N-{4-[3-chloro-4-(3-fluoro-benzyloxy)phenylamino]-quinazolin-6-yl}-acrylamide as exemplified by formula (I), methods of preparation thereof, pharmaceutical compositions comprising the same and their use thereof. The salt forms of the present invention, which possess excellent tumor inhibitory activity, good bioavailability and low toxicity in an animal body, are suitable for use of preparation of anti-tumor medicaments.Type: GrantFiled: February 4, 2008Date of Patent: January 8, 2013Assignee: Shanghai Allist Pharmaceuticals, Inc.Inventors: Jianhui Guo, Yong Jiang
-
Patent number: 8338438Abstract: The present invention relates to polymorphic forms of N-{4-[3-chloro-4-(3-fluoro-benzyloxy)phenylamino]-quinazolin-6-yl}-acrylamide p-toluenesulfonate with the characteristic X-ray powder diffraction data as stated in the description, preparation methods thereof, pharmaceutical compositions comprising the same and the use thereof.Type: GrantFiled: March 25, 2009Date of Patent: December 25, 2012Assignee: Shanghai Allist Pharmaceuticals, Inc.Inventors: Jianhui Guo, Yong Jiang
-
Patent number: 8309563Abstract: he present invention has disclosed a compound of formula I and a pharmaceutically acceptable salt or a solvate thereof, wherein the substituents are as defined in the description. The invention has also disclosed a method for preparing the compound of formula I, the pharmaceutical compositions comprising the same and their uses in the preparation of an anti-tumor medicament.Type: GrantFiled: June 14, 2011Date of Patent: November 13, 2012Assignee: Shanghai Allist Pharmaceuticals, Inc.Inventors: Jianhui Guo, Meng Wang, Yong Jiang, Xiaofang Zhang
-
Patent number: 8178569Abstract: The invention provides the crystalline imidazole-5-carboxylic acid derivative (I, the chemical name: 2-butyl-4-chloro-1-[2?-(1H-tetrazol-5-yl) 1,1?-biphenyl-methyl]-imidazole-5-carboxylic acid, 1-[(isopropoxy)-carbonyloxy]methyl ester), its preparation method and uses thereof.Type: GrantFiled: October 10, 2008Date of Patent: May 15, 2012Assignee: Shanghai Allist Pharmaceuticals, Inc.Inventors: Jianhui Guo, Dong An
-
Patent number: 8138214Abstract: The invention provides a new pharmaceutical compositions for treating cardiovascular disease, which contains the active component 2-butyl-4-chloro-1-[2?-(1H-tetrazol-5-yl)1,1?-biphenyl-methyl]imidazole-5-carboxylic acid, 1-[(isopropoxy)carbonyloxy]methyl ester dispersing in pharmaceutically acceptable carriers. The composition can be prepared to solid dosage forms e.g. powders, granules, dripping pills, micro-pellets, tablets, capsules, lozenges etc. by mouth or other way e.g. sublingual administration etc.Type: GrantFiled: July 2, 2009Date of Patent: March 20, 2012Assignee: Shanghai Allist Pharmaceutical, Inc.Inventors: Yaoru Lu, Jianhui Guo
-
Patent number: 8044063Abstract: The present invention relates to quinazoline derivatives of the formula (I) useful as anti-tumor medicaments, or a pharmaceutically acceptable salt thereof, the definition of the substituents R1, R1?, R2, R2? are as defined in the description. It also relates to a pharmaceutical composition containing same, and a method for the preparation of quinazoline derivatives of formula (I) or a pharmaceutically acceptable salt thereof.Type: GrantFiled: October 20, 2006Date of Patent: October 25, 2011Assignee: Shanghai Allist Pharmaceuticals, Inc.Inventors: Jianhui Guo, Meng Wang, Yong Jiang, Xiaofang Zhang
-
Publication number: 20110245246Abstract: he present invention has disclosed a compound of formula I and a pharmaceutically acceptable salt or a solvate thereof, wherein the substituents are as defined in the description. The invention has also disclosed a method for preparing the compound of formula I, the pharmaceutical compositions comprising the same and their uses in the preparation of an anti-tumor medicament.Type: ApplicationFiled: June 14, 2011Publication date: October 6, 2011Applicant: SHANGHAI ALLIST PHARMACEUTICALS, INC.Inventors: Jianhui Guo, Meng Wang, Yong Jiang, Xiaofang Zhang
-
Patent number: 7943648Abstract: The present invention provides pharmaceutically acceptable salts of imidazole-5-carboxylic acid derivatives, methods for preparing same and pharmaceutical compositions comprising same. The salts obtained by the present invention can be easily dissolved in common solvents, such as water and methanol. The bioavailability thereof is good in animal body. Thereby it is applicable to be developed as a normal preparation for treating hypertension.Type: GrantFiled: June 5, 2009Date of Patent: May 17, 2011Assignee: Shanghai Allist Pharmaceutical Inc.Inventors: Jianghui Guo, Dong An
-
Patent number: 7858651Abstract: The invention discloses imidazole-5-carboxylic acid derivatives, and their preparation methods. The derivatives of the invention are Angiotensin II receptor antagonists with angiotensin II antagonistic activity and antihypertensive activity, and thereby can be used as a therapeutical agent to treat hypertension.Type: GrantFiled: July 31, 2006Date of Patent: December 28, 2010Assignee: Shanghai Allist Pharmaceutical, Inc.Inventors: Jianhui Guo, Dong An
-
Publication number: 20100168193Abstract: The invention discloses the use of 2-butyl-4-chloro-1-[2?-(1H-tetrazol-5-yl)1,1?-biphenyl-methyl]-imidazole-5-carboxylic acid, 1-[(isopropoxycarbonyl)oxy] methyl ester and the pharmaceutically acceptable salts thereof in the manufacture of a medicament for the treatment of the damage of a target organ caused by hypertension. It particularly discloses the use of this compound in the manufacture of a medicament for the treatment of left ventricular hypertrophy, renal dysfunction, aorta thickening caused by hypertension, which provides an effective drug and method for the treatment of the damage of target organs for hypertension patients.Type: ApplicationFiled: June 6, 2008Publication date: July 1, 2010Applicant: SHANGHAI ALLIST PHARMACEUTICALS, INC.Inventor: Jianhui Guo
-
Publication number: 20080300248Abstract: The present invention has disclosed a compound of formula I and a pharmaceutically acceptable salt or a solvate thereof, wherein the substituents are as defined in the description. The invention has also disclosed a method for preparing the compound of formula I, the pharmaceutical compositions comprising the same and their uses in the preparation of an anti-tumor medicament.Type: ApplicationFiled: October 20, 2006Publication date: December 4, 2008Applicant: SHANGHAI ALLIST PHARMACEUTICALS, INC.Inventors: Jianhui Guo, Meng Wang, Yong Jiang, Xiaofang Zhang